Investigational antimicrobial drugs for bloodstream infections

Current Opinion in Investigational Drugs

Volumn 9, Issue 8, 2008, Pages 871-878

  Korbila, I P ^a,b   Falagas, M E ^a,c,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b 417 Army Share Found Hospital   (Greece)

^c HENRY DUNANT HOSPITAL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acinetobacter; Bacteremia; Candidemia; Ceftobiprol; Colistin; Dalbavancin; Humal lactoferrin peptide 1 11; Iclaprim; Isavuconazole; Klebsiella; Oritavancin; Polymyxin; Pseudomonas; Staphylococcus; Telavancin

Indexed keywords

4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; CEFALEXIN; CEFTOBIPROLE MEDOCARIL; COLISTIN; DALBAVANCIN; HUMAN LACTOFERRIN PEPTIDE[1-11]; ICLAPRIM; LACTOFERRIN; MDL 63397; MICAFUNGIN; ORITAVANCIN; POSACONAZOLE; RAVUCONAZOLE; TELAVANCIN; TRIAZOLE DERIVATIVE; VANCOMYCIN; VORICONAZOLE;

BACTEREMIA; BACTERIAL STRAIN; BLOODBORNE BACTERIUM; CANDIDEMIA; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESEARCH; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE COCCI; HUMAN; KLEBSIELLA; MEDICAL LITERATURE; MEDLINE; MULTIDRUG RESISTANCE; MYCOSIS; OSTEOMYELITIS; PNEUMONIA; PSEUDOMONAS; PUBLICATION; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTEREMIA; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, MULTIPLE; FUNGEMIA; HUMANS;

EID: 48349144902     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Grupper M, Sprecher H, Mashiach T, Finkelstein R: Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol (2007) 28(3):293-298.
2. Kang CI, Cheong HS, Chung DR, Peck KR, Song JH, Oh MD, Choe KW: Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis (2008) 27(1):85-88.
3. Laupland KB, Gregson DB, Flemons WW, Hawkins D, Ross T, Church DL: Burden of community-onset bloodstream infection: A population-based assessment. Epidemiol Infect (2007) 135(6):1037-1042. • Interesting population-based surveillance study of community-onset bloodstream infections and their impact on morbidity, mortality and length of hospital stay.
4. Fernandes P: Antibacterial discovery and development - the failure of success? Nat Biotechnol (2006) 24(12):1497-1503.
5. Wright GD, Sutherland AD: New strategies for combating multidrug-resistant bacteria. Trends Mol Med (2007) 13(6):260-267.
6. Micek ST: Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis (2007) 45(Suppl 3):S184-S190.
7. Rice LB: Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis (2006) 43(Suppl 2):S100-S105.
8. Rice LB: Antimicrobial resistance in Gram-positive bacteria. Am J Infect Control (2006) 34(5 Suppl 1):S11-S19.
9. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE: Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis (2007) 195(2):202-211.
10. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG: Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis (2006) 42(5):657-668. • An important review and position paper from the relevant committee of the Infectious Diseases Society of America on drugs in late-stage development that could potentially be effective against resistant pathogens.
11. Falagas ME, Kasiakou SK, Nikita D, Morfou P, Georgoulias G, Rafailidis PI: Secular trends of antimicrobial resistance of blood isolates in a newly founded Greek hospital. BMC Infect Dis (2006) 6:99.
12. Falagas ME, Bakossi A, Pappas VD, Holevas PV, Bouras A, Stamata E: Secular trends of blood isolates in patients from a rural area population hospitalized in a tertiary center in a small city in Greece. BMC Microbiol (2006) 6:41.
13. Hajjeh RA, Sofair AN, Harrison LH, Lynn GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J, Lee-Yang W, Ciblak MA, Benjamin LE et al: Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol (2004) 42(4):1519-1527.
14. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE et al: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 47(10):3149-3154.
15. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R et al: The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica (2006) 91(8):1068-1075. • A retrospective cohort study evaluating the incidence and outcome of invasive fungal infections between 1999 and 2003 in patients with hematological malignancies.
16. Farowski F, Vehreschild JJ, Cornely OA: Posaconazole: A next-generation triazole antifungal. Future Microbiol (2007) 2:231-243.
17. Kim R, Khachikian D, Reboli AC: A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin Pharmacother (2007) 8(10):1479-1492.
18. Vehreschild JJ, Cornely OA: Micafungin sodium, the second of the echinocandin class of antifungals: Theory and practice. Future Microbiol (2006) 1:161-170.
19. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis (2001) 32(5):686-693.
20. Mishra NN, Prasad T, Sharma N, Payasi A, Prasad R, Gupta DK, Singh R: Pathogenicity and drug resistance in Candida albicans and other yeast species. A review. Acta Microbiol Immunol Hung (2007) 54(3):201-235.
21. Seifert H, Aurbach U, Stefanik D, Cornely O: In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother (2007) 51(5):1818-1821.
22. Warn PA, Sharp A, Denning DW: In vitro activity of a new triazole BAL-4815, the active component of BAL-8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother (2006) 57(1):135-138.
23. Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle M: Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL-4815 after intravenous infusion and oral administration of its prodrug, BAL-8557, in healthy volunteers. Antimicrob Agents Chemother (2006) 50(1):286-293.
24. Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, Roehrle M, Beglinger C: Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL-4815 after intravenous infusions (50, 100, and 200 mg) and oral administrations (100, 200, and 400 mg) of its prodrug, BAL-8557, in healthy volunteers. Antimicrob Agents Chemother (2006) 50(1):279-285.
25. Viljoen JJ, Mitha I, Heep M, Ghannoum M: Efficacy, safety, and tolerability of three different dosing regimens of BAL-8557 vs fluconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis in immunocompromised adults. ICAAC (2005) 45:Abs LB2-32.
26. Pharmaceutica AG: Basilea's antifungal meets phase II candidiasis endpoint. Press Release (2005): September 08.
27. Ceftobiprole medocaril: BAL-5788, JNJ-30982081, JNJ-30982081, RO-65-5788, RO-655788. Drugs R D (2006) 7(5):305-311.
28. Guignard B, Entenza JM, Moreillon P: β-Lactams against methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol (2005) 5(5):479-489.
29. Page MG: Anti-MRSA β -lactams in development. Curr Opin Pharmacol (2006) 6(5):480-485.
30. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS: A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis (2008) 46(5):647-55.
31. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS: Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob Agents Chemother (2008) 52(1):37-44.
32. Lentino JR, Narita M, Yu VL: New antimicrobial agents as therapy for resistant Gram-positive cocci. Eur J Clin Microbiol Infect Dis (2008) 27(1):03-15. • An extended review on licensed and experimental antibiotics with activity against vancomycin-resistant and methicillin-resistant Gram-positive cocci.
33. Ward KE, Mersfelder TL, LaPlante KL: Oritavancin - an investigational glycopeptide antibiotic. Expert Opin Investig Drugs (2006) 15(4):417-429. • An evaluation of the antimicrobial activity, mechanism of action, pharmacodynamics, pharmacokinetics and safety of oritavancin.
34. Allen NE, Nicas TI: Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev (2003) 26(5):511-532.
35. Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG: Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis (2004) 50(2):95-102.
36. Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR Jr: Pharmacodynamics of oritavancin (LY-333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother (2003) 47(5):1700-1706.
37. Bhavnani SM, Passarell JA, Owen JS, Loutit JS, Porter SB, Ambrose PG: Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2006) 50(3):994-1000.
38. Wasilewski M, Disch DP, McGill JM, Harris HW, O'Riordan W, Zeckel ML: Equivalence of shorter course therapy with oritavancin vs vancomycin cephalexin in complicated skin/skin structure infections. ICAAC (2001) 41: Abs UL-18.
39. InterMune Inc: InterMune presents oritavancin data at 43rd Interscience Conference On Antimicrobial Agents and Chemotherapy. Press Release (2003): September 13.
40. Pipeline-Oritavancin program: Targanta Therapeutics, Quebec, Canada (2008): June 10. http://www.targanta.com/pipeline/oritavancin.html.
41. Malabarba A, Goldstein BP: Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother (2005) 55(Suppl 2):ii15-ii20.
42. Steiert M, Schmitz FJ: Dalbavancin (Biosearch Italia/Versicor). Curr Opin Investig Drugs (2002) 3(2):229-233.
43. Kahne D, Leimkuhler C, Lu W, Walsh C: Glycopeptide and lipoglycopeptide antibiotics. Chem Rev (2005) 105(2):425-448.
44. Streit JM, Sader HS, Fritsche TR, Jones RN: Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis (2005) 53(4):307-310.
45. Streit JM, Fritsche TR, Sader HS, Jones RN: Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis (2004) 48(2):137-143. • In this study, dalbavancin and more than 20 comparator agents were tested against 6,339 clinical isolates from the US and Europe, with the drug exhibiting superior activity.
46. Andes DR, Craig WA: In vivo pharmacodynamic characterization of dalbavancin in the murine thigh infection model. ICAAC (2004) 44: Abs 1872.
47. Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, Mroszczak EJ, Campbell KC, Kelly E: Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother (2004) 48(3):940-945.
48. Seltzer E, Goldberg L, Krause D: Safety of dalbavancin in a clinical development program. ICAAC (2005) 45: Abs L1576.
49. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T: Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis (2003) 37(10):1298-1303.
50. Goldstein BP, Seltzer E, Flamm R, Sahm D: Dalbavancin phase III skin and skin structure studies: Pathogens and microbiological efficacy. ICAAC (2005) 45: Abs L1577.
51. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, Krause D, Satilovs I, Endzinas Z, Breaux J, O'Riordan W: Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis (2005) 41(10):1407-1415.
52. Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H, Goldstein B, Henkel T, Seltzer E: Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis (2005) 40(3):374-380.
53. Pfizer Inc: Pfizer receives approvable letter from FDA for dalbavancin. Press Release (2007): December 21.
54. Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q et al: Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2005) 49(3):1127-1134.
55. Leuthner KD, Cheung CM, Rybak MJ: Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother (2006) 58(2):338-343.
56. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S: Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother (2005) 49(1):195-201.
57. Theravance Inc: Theravance receives FDA approvable letter for telavancin for the treatment of complicated skin and skin structure infections. Press Release (2007): October 21.
58. NCT00062647: Telavancin (TD 6424, ARBELIC™) for treatment of uncomplicated Staphylococcus aureus bacteremia. NIH, Bethesda, MD, USA (2006). http://clinicaltrials.gov/ct2/show/NCT00062647? term=NCT00062647&rank=1.
59. Falagas ME, Kasiakou SK: Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis (2005) 40(9):1333-1341. • A useful review on the chemistry/structure, mechanism of action, pharmacokinetic/pharmacodynamic properties, spectrum of activity, adverse effects, in vitro susceptibility of various pathogens, and clinical use of colistin.
60. Kwa A, Kasiakou SK, Tam VH, Falagas ME: Polymyxin B: Similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther (2007) 5(5):811-821.
61. Falagas ME, Kasiakou SK: Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care (2006) 10(1):R27.
62. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A: Nephrotoxicity of intravenous colistin: A prospective evaluation. Int J Antimicrob Agents (2005) 26(6):504-507.
63. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A: Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis (2005) 5(1):1.
64. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K: Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother (2003) 47(4):1364-1370.
65. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J: Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother (2003) 52(6):987-992.
66. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME: Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother (2005) 49(8):3136-3146.
67. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L: Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care (2003) 7(5):R78-R83.
68. NCT00300560: Efficacy and safety of colistin for therapy of infections caused by ESBL-producing K pneumoniae or E coli. NIH, Bethesda, MD, USA (2006). http://clinicaltrials.gov/ct2/show/ NCT00300560?term=NCT00300560&rank=1.
69. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett (2003) 13(23):4217-4221.
70. Arpida Ltd: Arpida completes enrolment in phase III trial with intravenous iclaprim. Press Release (2007): March 22.
71. Arpida Ltd: Arpida receives approval from US FDA to initiate a phase II trial with iclaprim in hospital-acquired, ventilator and healthcare- associated pneumonia. Press Release (2007): June 21.
72. Peppard WJ, Schuenke CD. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs (2008) 9(2):210-225.
73. Kohlhoff SA, Sharma R. Iclaprim. Expert Opin Investig Drugs (2007) 16(9):1441-1448.
74. Dijkshoorn L, Brouwer CP, Bogaards SJ, Nemec A, van den Broek PJ, Nibbering PH: The synthetic N-terminal peptide of human lactoferrin, hLF 1-11, is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2004) 48(12):4919-4921.
75. Lupetti A, Paulusma-Annema A, Welling MM, Dogterom-Ballering H, Brouwer CP, Senesi S, Van Dissel JT, Nibbering PH: Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob Agents Chemother (2003) 47(1):262-267.
76. Stallmann HP, Faber C, Bronckers AL, de Blieck-Hogervorst JM, Brouwer CP, Amerongen AV, Wuisman PI: Histatin- and lactoferrin-derived peptides: Antimicrobial properties and effects on mammalian cells. Peptides (2005) 26(12):2355-2359.
77. Zimecki M, Wlaszczyk A, Wojciechowski R, Dawiskiba J, Kruzel M: Lactoferrin regulates the immune responses in post-surgical patients. Arch Immunol Ther Exp (Warsz) (2001) 49(4):325-333.
78. AM-Pharma BV: Dutch biopharmaceutical company AM-Pharma strengthens intellectual property position for lactoferrin-derived antimicrobial peptide hLF 1-11. Press Release (2006): August 10.
79. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A: Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis (2005) 5(1):24.
80. Falagas ME, Fragoulis KN, Karydis I: A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. PLoS ONE (2006) 20(1):e11.